October 25, 2017
Kite Pharma to Present at the Citi 9th Annual Biotech Conference on Wednesday, September 3
SANTA MONICA, Calif., Aug. 26, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced its participation at Citi's 9th Annual Biotech Conference at the Mandarin Oriental in Boston on Wednesday, September 3rd, at 6:00pm ET. Arie Belldegrun, M.D., FACS, President and Chief Executive Officer, will discuss Kite's development efforts on a panel titled, "How CAR-T Cell Therapies are Shaping Oncology's Future."
About Kite Pharma, Inc.
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing novel immunotherapies and other oncology treatments. Kite is based in Santa Monica, CA.
CONTACT: Kite Pharma Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson For Investor Inquiries: Kimberly Minarovich Burns McClellan 212-213-0006 firstname.lastname@example.org email@example.com